Physician profile
Arvind Bhasker
NPI 1932595121
$480.80
in general payments reported to CMS, 2019-2025
11 companies · $17.26 in 2025
The $17.26 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.22 · 2020: $107 · 2021: $258 · 2022: $33.30 · 2024: $16.22 · 2025: $17.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $206.33 | 2021-2025 | |
| Lundbeck LLC | $68.20 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.02 | 2020-2022 | |
| Allergan, INC. | $37.72 | 2020 | |
| Alkermes, INC. | $24.10 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.42 | 2022 | |
| Neuronetics, INC. | $16.22 | 2024 | Neurostar Tms Therapy System |
| Avanir Pharmaceuticals, INC. | $14.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.23 | 2021 | |
| Shire North American Group INC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Bhasker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.